John Brognard

8PUBLICATIONS
54CO-AUTHORS
Molecular targetsAdversarial machine learningBasic pharmacologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 02, 2026
Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.

|May 25, 2026
A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers.

|Jun 10, 2025
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.

Andrii Gorelik, Joao A Paulo, Christina B Schroeter

|Feb 11, 2025
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.

Amy L Funk, Meghri Katerji, Marwa Afifi

|Aug 16, 2024
Dual inhibition of EGFR and PI3K with a single drug.

Meghri Katerji, Maxine R Rubin, John Brognard

|Jun 10, 2024
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.

Triet Nguyen, Francesca A Carrieri, Nick Connis

Pageof 2

Frequent Collaborators

3 joint publications

Ivan Ahel

3 joint publications

Pedro Torres-Ayuso

2 joint publications

Tung Hoang

2 joint publications

Amol C Shetty